Evidence from the placement of aortic transcatheter valve (PARTNER) trial—can we just dismiss it?
- 2 Downloads
In a recent review titled “TAVI—thick on technology but thin on evidence,” Dr. Sarkar has raised many pertinent issues related to the adoption of transcatheter aortic valve implantation (TAVI) in general and the placement of aortic transcatheter valve (PARTNER) trial in particular .
The review has to be lauded for highlighting some very important issues regarding lack of data transparency and publication bias and bringing forward the many clinical concerns with transcatheter aortic valve replacement (TAVR) or TAVI. However, some of the criticism is a little harsh, and for the benefit of the readership, the positives of the trial need to be stressed upon too.
One of the criticisms of the trial in the review was lack of any substantive differences between the inoperable (cohort B) and high-risk operable groups (cohort A), implying that the criteria to choose who was high risk and who was deemed inoperable was flawed. However, the inoperability was decided not just on clinical but also...
Compliance with ethical standards
Conflict of interest
The author declares no conflict of interest.
The invited editorial does not mention any patient or patient details, and hence, formal ethical approval is not required.
- 1.Sarkar K. TAVI—thick on technology but thin on evidence. Indian J Thorac Cardiovasc Surg. 2018. https://doi.org/10.1007/s12055-018-0731-2.